InsiderTrades.com logo
Protect Yourself While There’s Still Time …
From Weiss Ratings   |   Ad
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
4 simple steps to protect your privacy and money before it’s too late.
Michelle Gilson net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Michelle Gilson Biography and Net Worth

CFO of Arcellx

Michelle Gilson joined Arcellx, Inc. as our chief financial officer in May 2022. Most recently, Ms. Gilson served as a Managing Director and Senior Equity Research Analyst at Canaccord Genuity, covering biotechnology companies. Prior to joining Canaccord, Ms. Gilson held biotechnology equity research roles at Jefferies, LLC; Instinet, LLC (Nomura Securities); Oppenheimer & Co. Inc.; and Goldman Sachs. Ms. Gilson earned her B.S. in Business Administration from the University of Southern California.

What is Michelle Gilson's net worth?

The estimated net worth of Michelle Gilson is at least $492,461.20 as of March 18th, 2024. Ms. Gilson owns 9,485 shares of Arcellx stock worth more than $492,461 as of April 27th. This net worth evaluation does not reflect any other assets that Ms. Gilson may own. Additionally, Ms. Gilson receives a salary of $832,800.00 as CFO at Arcellx. Learn More about Michelle Gilson's net worth.

How old is Michelle Gilson?

Ms. Gilson is currently 31 years old. There are 5 older executives and no younger executives at Arcellx. The oldest executive at Arcellx is Mr. David Tice Ph.D., Chief Scientific Officer, who is 53 years old. Learn More on Michelle Gilson's age.

What is Michelle Gilson's salary?

As the CFO of Arcellx, Inc., Ms. Gilson earns $832,800.00 per year. The highest earning executive at Arcellx is Mr. Rami Elghandour, Chairman of the Board, CEO & President, who commands a salary of $1,020,000.00 per year. Learn More on Michelle Gilson's salary.

How do I contact Michelle Gilson?

The corporate mailing address for Ms. Gilson and other Arcellx executives is , , . Arcellx can also be reached via phone at 240-327-0603 and via email at [email protected]. Learn More on Michelle Gilson's contact information.

Has Michelle Gilson been buying or selling shares of Arcellx?

Michelle Gilson has not been actively trading shares of Arcellx in the last ninety days. Most recently, Michelle Gilson sold 6,825 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $69.34, for a transaction totalling $473,245.50. Following the completion of the sale, the chief financial officer now directly owns 9,485 shares of the company's stock, valued at $657,689.90. Learn More on Michelle Gilson's trading history.

Who are Arcellx's active insiders?

Arcellx's insider roster includes Jill Carroll (Director), Rami Elghandour (Chairman and Chief Executive Officer), Michelle Gilson (CFO), and Christopher Heery (Chief Medical Officer). Learn More on Arcellx's active insiders.

Are insiders buying or selling shares of Arcellx?

In the last year, insiders at the sold shares 21 times. They sold a total of 2,610,344 shares worth more than $131,625,355.83. The most recent insider tranaction occured on April, 16th when Director Olivia C. Ware sold 9,402 shares worth more than $522,281.10. Insiders at Arcellx own 6.2% of the company. Learn More about insider trades at Arcellx.

Information on this page was last updated on 4/16/2024.

Michelle Gilson Insider Trading History at Arcellx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/18/2024Sell6,825$69.34$473,245.509,485View SEC Filing Icon  
1/4/2024Sell8,514$55.27$470,568.7816,310View SEC Filing Icon  
5/24/2023Sell8,704$42.46$369,571.8415,485View SEC Filing Icon  
See Full Table

Michelle Gilson Buying and Selling Activity at Arcellx

This chart shows Michelle Gilson's buying and selling at Arcellx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arcellx Company Overview

Arcellx logo
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $51.92
Low: $50.87
High: $52.68

50 Day Range

MA: $64.10
Low: $51.38
High: $73.49

2 Week Range

Now: $51.92
Low: $30.74
High: $75.10

Volume

339,688 shs

Average Volume

452,241 shs

Market Capitalization

$2.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02
Protect Yourself While There’s Still Time …
From Weiss Ratings   |   Ad
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
4 simple steps to protect your privacy and money before it’s too late.